Literature DB >> 2138126

Allograft rejection in athymic nude rats by transferred T-cell subsets. I. The response of naive CD4+ and CD8+ thoracic duct lymphocytes to complete allogeneic incompatibilities.

E H Whitby1, S M Sparshott, E B Bell.   

Abstract

PVG.rnu/rnu nude rats were pre-grafted with two allogeneic skin grafts, AO(RTlu) and BN(RTln), 6-14 days in advance of cell transfer. Cellular requirements for rejection were established by transferring graded numbers of B cell-depleted (Ig-) thoracic duct lymphocytes (TDL) or purified W3/25+ (CD4+) or OX8+ (CD8+) TDL subsets. Allografts were rejected by 10(5) to 5 x 10(6) Ig- TDL in a dose-dependent fashion. A similar dose-response relationship was found by transferring 5 x 10(5) to 5 x 10(6) Ig- OX8- TDL (purified by depletion of B cells and OX8+ cells). Larger numbers of Ig- OX8- TDL (10-30 x 10(6)) did not significantly accelerate rejection. W3/25+ TDL alone (10(5)), highly purified by fluorescence-activated cell sorting (FACS), were sufficient to induce allograft rejection in this athymic nude rat model. In contrast, 10 times more FACS purified OX8+ TDL (10(6)) were unable to initiate skin graft rejection despite the complete class I and class II MHC incompatibilities. Furthermore, the addition of 10(6) OX8+ cells did not accelerate or retard the rejection induced by 10(5) W3/25+ cells alone. Pre-grafted nude recipients, irradiated (500 R) 2 hr before W3/25+ TDL injection, in order to eliminate putative nude T cells, rejected allografts on the same day as unirradiated controls. We conclude that when confronted with complete MHC disparities, CD4+ T cells are necessary and sufficient to induce skin allograft rejection whereas CD8+ T cells do not appear to contribute.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138126      PMCID: PMC1385723     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  39 in total

Review 1.  Nude mice in immunology.

Authors:  B Kindred
Journal:  Prog Allergy       Date:  1979

2.  Specific inhibition of natural killer (NK) activity against different alloantigens.

Authors:  S Fossum; A Ager; B Rolstad
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

3.  Lympho-stromal interactions in the thymus: medullary thymocytes react with I-A determinants on autochthonous thymic stimulator cells.

Authors:  W Born; H Wekerle
Journal:  Eur J Immunol       Date:  1982-01       Impact factor: 5.532

4.  Age-associated increase in expression of the T cell surface markers Thy-1, Lyt-1, and Lyt-2 in congenitally athymic (nu/nu) mice: analysis by flow microfluorometry.

Authors:  H R MacDonald; R K Lees; B Sordat; P Zaech; J L Maryanski; C Bron
Journal:  J Immunol       Date:  1981-03       Impact factor: 5.422

5.  Immunoperoxidase localization of large granular lymphocytes in normal tissues and lesions of athymic nude rats.

Authors:  J M Ward; F Argilan; C W Reynolds
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

6.  The architecture of rat lymph nodes. III. The lymph nodes and lymph-borne cells of the congenitally athymic nude rat (rnu).

Authors:  S Fossum; M E Smith; E B Bell; W L Ford
Journal:  Scand J Immunol       Date:  1980       Impact factor: 3.487

7.  The cellular basis of allograft rejection in vivo. I. The cellular requirements for first-set rejection of heart grafts.

Authors:  B M Hall; S Dorsch; B Roser
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

8.  The in vitro generation and sustained culture of nude mouse cytolytic T-lymphocytes.

Authors:  S Gillis; N A Union; P E Baker; K A Smith
Journal:  J Exp Med       Date:  1979-06-01       Impact factor: 14.307

9.  Cells mediating graft rejection in the mouse. I. Lyt-1 cells mediate skin graft rejection.

Authors:  B E Loveland; P M Hogarth; R Ceredig; I F McKenzie
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

10.  Specificity of cytotoxic T cells from athymic mice.

Authors:  T Hünig; M J Bevan
Journal:  J Exp Med       Date:  1980-09-01       Impact factor: 14.307

View more
  7 in total

1.  Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody.

Authors:  W Ayliffe; Y Alam; E B Bell; D McLeod; I V Hutchinson
Journal:  Br J Ophthalmol       Date:  1992-10       Impact factor: 4.638

2.  T-cell receptor-bearing cells from athymic nude rats respond to alloantigen in vitro but are defective in vivo.

Authors:  S R Sarawar; C P Yang; E B Bell
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

Review 3.  Escaping from rejection.

Authors:  Raymond J Lynch; Jeffrey L Platt
Journal:  Transplantation       Date:  2009-12-15       Impact factor: 4.939

4.  T lymphocytes are not required for the development of fatty degeneration after rotator cuff tear.

Authors:  J Gumucio; M Flood; J Harning; A Phan; S Roche; E Lynch; A Bedi; C Mendias
Journal:  Bone Joint Res       Date:  2014-09       Impact factor: 5.853

5.  The Transcription Factor NFATc1 Supports the Rejection of Heterotopic Heart Allografts.

Authors:  Johannes Baur; Christoph Otto; Ulrich Steger; Stefan Klein-Hessling; Khalid Muhammad; Tobias Pusch; Krisna Murti; Rhoda Wismer; Christoph-Thomas Germer; Ingo Klein; Nora Müller; Edgar Serfling; Andris Avots
Journal:  Front Immunol       Date:  2018-06-12       Impact factor: 7.561

6.  Major histocompatibility complex-expressing nonhematopoietic astroglial cells prime only CD8+ T lymphocytes: astroglial cells as perpetuators but not initiators of CD4+ T cell responses in the central nervous system.

Authors:  J D Sedgwick; R Mössner; S Schwender; V ter Meulen
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

7.  T cell deficiency in spinal cord injury: altered locomotor recovery and whole-genome transcriptional analysis.

Authors:  David Satzer; Catherine Miller; Jacob Maxon; Joseph Voth; Christina DiBartolomeo; Rebecca Mahoney; James R Dutton; Walter C Low; Ann M Parr
Journal:  BMC Neurosci       Date:  2015-11-06       Impact factor: 3.288

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.